Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Alliance Global Partners Downgrades Alimera Sciences to Neutral, Lowers Price Target to $4.5
Alliance Global Partners analyst James Molloy downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral and lowers the price target from $11 to $4.5.
Alimera Sciences Q3 EPS $(0.75) Misses $(0.40) Estimate, Sales $13.60M Miss $15.17M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.40) by 87.5 percent. This is a 25 percent decrease over losses of $(0.60) per share from
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Alimera Announces Agreement With Jaeb Center For Health Research On Behalf Of The DRCR Retina Network To Support And Provide Iluvien 0.19 Mg Sustained Release Intravitreal Implant
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned
Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real World Data At EURETINA Annual Congress Hamburg, Germany September 1-4
ATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.
Alimera Announces Pricing, Reimbursement Of Uveitis Indication Granted For ILUVIEN In France
Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining
Alimera Sciences Announces Phase 4 PALADIN Study On Predictive Value Of Corticosteroid Course Prior To ILUVIEN Use For IOP Outcomes
Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better